LDS/Medical Tests/Mucolipidosis Type IV (MCOLN1) Mutation Analysis

Mucolipidosis Type IV (MCOLN1) Mutation Analysis

Mucolipidosis IV is an autosomal recessive disorder affecting ~70% of individuals with Ashkenazi Jewish ancestry. Mucolipidosis IV is a neurodegenerative disease characterized by severe psychomotor delay with slow progression of visual impairment during the first ten years and by teenage years having severe visual impairment as a result of retinal degeneration. Individuals with mucolipidosis are treated with physical therapy, speech therapy, antiepileptic drugs, eye drops, and ointments for eye irritation.

Clinical testing strategies for mucolipidosis IV include: 1) confirmation testing to diagnose the disease, 2) predictive testing of carrier status, and 3) prenatal testing to determine status of a fetus with a family history of mucolipidosis IV. Confirmation of disease status provides proper patient care and genetic information for at-risk relatives. Predictive testing determines genetic risk for individuals who have a family history of mucolipidosis IV. Prenatal testing can be performed if both disease-causing alleles are identified in the family.

Mucolipidosis IV is caused by mutations in the MCOLN1 gene located on chromosome 19, specifically the 19p13.3-p13.2 region. The MCOLN1 gene provides instructions for making the protein mucolipin-1. This protein is thought to play a role in the transport of lipids and proteins between lysosomes and endosomes. Likewise, mucolipin-1 is important for proper development and maintenance of the brain and retina. No other phenotypes are associated with mutations in MCOLN1.

Mucolipidosis IV is diagnosed by molecular genetic testing of the MCOLN1 gene. The molecular basis of mucolipidosis provides key factors for detection and predictive patient impacts. Molecular testing such as targeted mutation analysis, DNA sequence analysis, and deletion/duplication analysis is used to determine the specific mutations. The two mutations that account for more than 95% of mutant alleles in individuals of Ashkenazi Jewish ancestry and thus are responsible for the majority of mucolipidosis IV occurrences are c.406-2A>G and g.511_6943del.

Carrier testing for individuals of Ashkenazi Jewish ancestry Diagnose Mucolipidosis Type IV Confirmation of disease diagnosis Prenatal diagnosis Determine carrier status
Heterozygous mutations on c.406-2A>G and g.511_6943del might indicate carrier status. Homozygous or compound heterozygous mutations might indicate disease.

Negative for mutation analyzed


Plasma gastrin concentration (elevated in patients with the disease due to achlorhydria):
· Mucolipidosis IV: 400-4100 pg/mL
· Normal: 0-200 pg/mL
 

 

 

Targeted mutation analysis (Mutations c.406-2A>G, g.511_6943del), DNA sequencing analysis that detects sequence variants including c.406-2A>G and g.511_6943del, Deletion/duplication analysis by Quantitative polymerase chain reaction (qPCR) or by Multiplex ligation dependent probe amplification (MLPA), Gene segment specific analysis.

Whole Blood EDTA (Lavender) or ACD (Yellow) preferred, Heparin (Green) acceptable.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Plasma gastrin, Skin biopsy or conjunctiva swab (Demonstrates accumulation of abnormal lamellar membrane structures and undefined cytoplasmic inclusions in different cell types), Ashkenazi Jewish panel, Liver profile.

1-2 weeks.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login